NIHON PARKERIZING CO.,LTD. FY2027 Q1 Earnings Report

Financial Highlights

• Net Sales: ¥33.67B
• Operating Income: ¥4.74B
• Net Income: ¥4.17B
• EPS: ¥34.12

Income Statement

Balance Sheet

Profitability Ratios

Year-over-Year Comparison

Share Information

Segment Information

Full Year Forecast

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong quarter, with solid top-line growth and notable margin expansion driving double-digit profit gains. Revenue rose 5.6% YoY to 336.7bn JPY, while operating income surged 38.8% YoY to 47.37bn JPY. Ordinary income increased 48.4% YoY to 59.86bn JPY, and net income attributable to owners grew 30.6% YoY to 36.71bn JPY. Gross margin held at 36.2%, and operating margin improved to 14.1%, up roughly 340 bps from about 10.7% a year ago. Net margin reached 10.9%, improving about 210 bps YoY. The jump in ordinary income reflects higher operating profit plus healthy non-operating income of 13.95bn JPY (about 4.1% of sales), including dividends of 4.28bn JPY, interest income of 1.00bn JPY, and FX gains of 1.45bn JPY. SG&A grew only 2.1% YoY versus revenue growth of 5.6%, supporting operating leverage. Segment-wise, Medicine remained the core profit engine with a 17.5% margin, while Equipment’s profitability rebounded sharply with a 12.5% margin on flat sales. Balance sheet strength is exceptional: net cash position with cash and deposits of 58.6bn JPY against interest-bearing debt of 2.5bn JPY, current ratio of 393%, and D/E of 0.21x. Interest coverage is extremely high at 2,368x, underscoring minimal financial risk. Comprehensive income was robust at 86.94bn JPY, aided by valuation gains on securities. Working capital efficiency indicators in the quality alerts point to elongated receivable and inventory cycles, which could temper cash conversion despite earnings strength. Against full-year guidance, Q1 progress is on or slightly ahead of plan: sales at 25.1%, operating income at 31.6%, ordinary income at 31.5%, and net income at 26.2%. Forward-looking, sustained cost discipline and segment mix should support margins, while attention to cash conversion and inventory discipline will be key to maintaining quality of earnings. Dividend guidance implies a conservative payout ratio supported by a strong balance sheet.

Profitability Analysis

ROE decomposition (DuPont 3-factor): NI margin 10.9% × Asset Turnover 0.125 × Financial Leverage 1.21x = ROE 1.6%. The largest positive change YoY is NI margin, driven by operating margin expansion (14.1% vs ~10.7% prior) and improved non-operating line (swing from prior FX losses to current FX gains, plus higher dividend income). Asset turnover improved modestly (sales growth against stable assets), while leverage was little changed and remains low. The business drivers include better SG&A efficiency (SG&A +2.1% vs sales +5.6%), improved segment profitability in Medicine and a sharp rebound in Equipment. These efficiency gains and mix improvements appear partially sustainable given cost control and segment performance; FX and market-related dividend income are less predictable and should be considered partially one-time or volatile. A healthy sign is that expense growth trailed revenue growth, indicating positive operating leverage.

Growth Assessment

Top-line grew 5.6% YoY, led by Medicine (+8.7%) and Processing (+4.6%), while Equipment was flat (-0.1%). Operating profit rose 38.8% YoY, with broad-based contribution: Medicine OP +16.9%, Processing OP +11.6%, and Equipment OP +675.2% on margin normalization. Ordinary income growth (+48.4%) benefited from non-operating gains (dividends, FX, equity-method income). Margin expansion was the primary driver of profit growth, supported by controlled SG&A and improved segment mix. The outlook embedded in guidance (flat-to-slight growth in operating income for the full year) appears achievable with Q1 tracking ahead on profitability. Sustainability hinges on maintaining segment margins in Medicine and Equipment and managing pricing/cost pass-through. Sensitivity to equity-related and FX income remains a swing factor for ordinary profit.

Financial Health

Liquidity is very strong: current ratio 393% and quick ratio 379%. The company is in a net cash position with cash and deposits of 58.6bn JPY versus interest-bearing debt of 2.5bn JPY; D/E is 0.21x and interest coverage is 2,368x. No warning thresholds are triggered (Current Ratio >> 1.0, D/E well below 2.0). Maturity mismatch risk is low given ample current assets relative to current liabilities (working capital of 86.3bn JPY). Balance sheet carries sizable investment securities (17.3% of assets), providing additional financial flexibility.

Notable B/S Changes

Treasury stock: -10.6% of total assets – sizable cumulative buybacks support per-share metrics and capital returns. Cash & deposits: 21.7% of total assets – substantial liquidity buffer enhances financial flexibility. Investment securities: 17.3% of total assets – meaningful market exposure influences comprehensive income.

Cash Flow Quality

Profit growth is supported by margin expansion and disciplined SG&A. Working capital efficiency indicators flagged (high DSO, elevated DIO, long CCC) suggest potential cash conversion drag and the need for tighter receivables collection and inventory management to align cash generation with earnings. Non-operating income contributed meaningfully to ordinary income, so monitoring the cash realization of dividends and stability of FX gains is important for earnings-to-cash conversion.

Dividend Sustainability

Full-year DPS guidance is 50 JPY with EPS guidance of 151.76 JPY, implying a payout ratio of approximately 33%, comfortably within sustainable levels. The net cash balance sheet and resilient operating profitability support dividend capacity. Given modest capital intensity and strong liquidity, the dividend outlook appears well-covered by ongoing earnings.

Risk Assessment

Business risks include Margin sustainability risk in Equipment after a sharp YoY rebound, Dependence on Medicine segment profitability (core profit concentration), Exposure to market-related income (dividends, equity-method) impacting ordinary profit.

Financial risks include Elongated working capital cycle (high DSO/DIO, long CCC) pressuring cash conversion, Equity market sensitivity via investment securities valuation affecting comprehensive income.

Key concerns include CAPITAL_EFFICIENCY: ROIC 2.0% indicates low capital efficiency versus typical 5–8% targets; with low asset turnover and a large equity base, incremental returns may lag unless growth accelerates or assets are optimized, HIGH_RECEIVABLE_DAYS: DSO 441 days suggests very slow collections; atypical for the industry and implies elevated counterparty risk and cash tied in receivables, HIGH_INVENTORY_DAYS: DIO 203 days indicates inventory build and potential obsolescence or demand-supply mismatch risk; requires closer S&OP discipline, LONG_CCC: Cash conversion cycle of 392 days signals structurally slow cash generation from operations relative to revenue, elevating working capital funding needs despite strong cash balance, HIGH_INVENTORY_DAYS: 69 days (alternative computation) still exceeds the <60 days benchmark, reinforcing the need for tighter inventory turns.

Investment Implications

Key takeaways include Strong Q1 with 340 bps operating margin expansion and 30%+ earnings growth, Non-operating tailwinds (dividends, FX) boosted ordinary income; core margins also improved, Exceptional balance sheet strength (net cash, low leverage) underpins resilience and dividends, Working capital efficiency is a watchpoint; high DSO/DIO could mute cash conversion, Guidance tracking is on or slightly ahead, particularly on operating profitability.

Metrics to watch include Operating margin sustainability by segment (Medicine ~17.5%, Equipment ~12.5%), DSO, DIO, and CCC trends for cash conversion, Contribution of non-operating income to ordinary profit (dividends, FX, equity-method), Progress vs full-year guidance (OI and NI progress rates), Inventory mix (raw materials vs finished goods) to gauge demand alignment.

Regarding relative positioning, Within Japanese specialty chemical/process treatment peers, the company stands out for balance sheet strength, conservative leverage, and solid mid-teens operating margin this quarter; however, capital efficiency and cash conversion trail best-in-class operators with tighter working capital cycles.